Header
Header
Article

Neurocognitive Impairment in Cardiovascular Disease Patients Taking Statins Versus Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: A Systematic Review



Review

. 2022 Oct 31;14(10):e30942.


doi: 10.7759/cureus.30942.


eCollection 2022 Oct.

Affiliations

Item in Clipboard

Review

Rabia Shahid et al.


Cureus.


.

Abstract

Cardiovascular diseases (CVDs) are prevalent medical conditions affecting millions of people worldwide and are associated with significant morbidity and mortality. The main precursor of CVDs and the related events, such as hypertension and heart failure, is hyperlipidemia, most commonly an increase in low-density lipoproteins. Lipid-lowering drugs are cardinal in the treatment of CVDs. American College of Cardiology and American Heart Association have issued guidelines for lipid-lowering therapy, and statins are first-line medication. In the recent years, a new class of lipid-lowering agents called proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has been identified as the potential lipid-lowering therapy for the statin-resistant patient. In clinical trials and observational studies, PCSK9 inhibitors and statins are both associated with the development of neurocognitive dysfunction in the older population. This systematic review aims to inquire if there is significant neurocognitive dysfunction associated with statins and PCSK9 inhibitors and compare neurocognitive effects associated with statins with those of PCSK9 inhibitors.


Keywords:

pcsk-9 inhibitors; pcsk9 inhibitors vs statins; pcsk9 neurocognitive effects; statins neurocognitive effects; subtilisin kexin neurocognitive effects.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures



Figure 1. Flowchart of the literature review search per PRISMA 2020 guidelines

PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-analyses

References

    1. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Grundy SM, Stone NJ, Bailey AL, et al. Circulation. 2019;139:0–81.



      PubMed

    1. Statins: mechanism of action and effects. Stancu C, Sima A. J Cell Mol Med. 2001;5:378–387.



      PMC



      PubMed

    1. Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: a frequentist network meta-analysis. Zhao Z, Du S, Shen S, Luo P, Ding S, Wang G, Wang L. Medicine (Baltimore) 2019;98:0.



      PMC



      PubMed

    1. Pharmacological options in atherosclerosis: a review of the existing evidence. Gupta KK, Ali S, Sanghera RS. Cardiol Ther. 2019;8:5–20.



      PMC



      PubMed

    1. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. J Am Coll Cardiol. 2002;40:567–572.



      PubMed



Source link

Back to top button